Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial

Article summary

Azitra, Inc. has amended its ongoing Phase 1/2 clinical trial of ATR04-484 to include patients with rashes associated with KRAS and MEK inhibitors, as well as those with neurofibromatosis type 1.